Nektar Therapeutics (NASDAQ:NKTR) Rating Reiterated by BTIG Research
BTIG Research reiterated their buy rating on shares of Nektar Therapeutics (NASDAQ:NKTR – Free Report) in a report published on Monday, MarketBeat.com reports. They currently have a $4.00 price objective on the biopharmaceutical company’s stock. Separately, Rodman & Renshaw started coverage on shares of Nektar Therapeutics in a research note on Friday, June 28th. They […]
More Stories
US Targets Houthi Positions in Yemen With Airstrikes
By Chase Smith U.S. forces conducted 15 strikes in Iranian-backed Houthi-controlled areas of Yemen, U.S. Central Command (CENTCOM), which oversees...
Gang attack in Haiti’s Pont Sondé leaves 70 dead
An attack by a notorious gang in the town of Pont Sondé, Haiti, left at least 70 people dead on...
Fixing America Overnight: Warren Buffet’s Radical Solution to Economic Stagnation
By Stephen Zogopoulos, USNN World News In the complex and often chaotic arena of U.S. politics, there are few people...
Analysts Set Outset Medical, Inc. (NASDAQ:OM) Price Target at $4.64
Shares of Outset Medical, Inc. (NASDAQ:OM – Get Free Report) have been given an average recommendation of “Hold” by the...
Columbia Banking System, Inc. (NASDAQ:COLB) Receives $25.42 Average Target Price from Brokerages
Shares of Columbia Banking System, Inc. (NASDAQ:COLB – Get Free Report) have earned an average rating of “Hold” from the...
Renasant Co. (NASDAQ:RNST) Receives Average Recommendation of “Moderate Buy” from Analysts
Shares of Renasant Co. (NASDAQ:RNST – Get Free Report) have been assigned an average rating of “Moderate Buy” from the...